Evaluating Drug-Drug Interactions: Implications of Phenoconversions

June 17, 2020
1 pm to 2 pm EDT

Sponsored by


Webinar Description:
This webinar will review drug-drug and drug-drug-gene interactions in the context of drug exposure. A foundation of drug exposure will be presented, followed a discussion of drug-drug and drug-drug-gene interactions. From this webinar, the participant will be able to:

1. Define the pharmacogenes related to drug absorption, distribution, metabolism, and excretion.

2. Describe how drug exposure is related to efficacy/inefficacy and adverse drug events.

3. Explain how pharmacogene variants influence or do not influence drug exposure.

4. Provide examples of drug-drug-gene interactions.



David Kisor imageDavid F. Kisor, Pharm.D., FCP
Professor of Pharmaceutical Sciences, Director of Pharmacogenomics Education
Manchester University

Director of Pharmacogenomics, joined Manchester University in June 2014 and is responsible for directing pharmacogenomics across programs in the College of Pharmacy, Natural and Health Sciences. He led the development and implementation of the first dedicated Master of Pharmacogenomics Program (MS in PGx) in the United States, helping to expand delivery to an online format, as well as helping to establish the first PharmD/MS in PGx dual degree program. He received his Bachelor of Science degree in Pharmacy from The University of Toledo and his Doctorate in Pharmacy from The Ohio State University. He completed a postdoctoral fellowship in therapeutic drug monitoring and pharmacokinetics at Ohio State. He has integrated pharmacogenetics and pharmacogenomics with pharmacokinetic subject matter since 1998. Beyond the formal academic setting, he is very engaged in pharmacogenomics education, having been involved with the American Association of Colleges of Pharmacy Pharmacogenomics Special Interest Group (AACP PGx SIG) in defining/refining competency statements for pharmacists as well as leading the effort to provide the first certification program in pharmacogenomics in the United States. He is a member of the American Pharmacists Association (APhA), the American College of Clinical Pharmacology (ACCP), the American Society for Clinical Pharmacology and Therapeutics (ASCPT), the American Association of Colleges of Pharmacy (AACP), and the Clinical Pharmacogenetics Implementation Consortium (CPIC). Dr. Kisor is a past chair of the AACP PGx SIG. He was named a fellow of ACCP in 2017.

Cost: No cost!